Palvella Therapeutics (NASDAQ:PVLA) Stock Price Target Raised at Canaccord Genuity Group

Key Points

• Canaccord Genuity raised its price target on Palvella Therapeutics to $243 from $232 and maintained a Buy rating, implying 39.36% upside from the stock’s then-current price.
• Analyst opinion is mostly positive: MarketBeat reports two Strong Buy, 12 Buy, and one Sell rating, with a consensus price target of $213.85.
• Palvella reported a quarterly loss of $1.70 per share, beating estimates of a $1.78 loss. Insiders sold 61,056 shares worth about $8.76 million over the prior quarter.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) had its target price lifted by research analysts at Canaccord Genuity Group from $232.00 to $243.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's target price indicates a potential upside of 39.36% from the stock's current price.

PVLA has been the topic of several other reports. HC Wainwright initiated coverage on shares of Palvella Therapeutics in a research note on Friday. They issued a "strong-buy" rating on the stock. Raymond James Financial set a $226.00 price objective on shares of Palvella Therapeutics in a research note on Friday, October 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Oppenheimer increased their target price on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Palvella Therapeutics has a consensus rating of "Buy" and a consensus price target of $213.85.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA traded down $1.55 during trading hours on Monday, reaching $174.37. 155,870 shares of the stock were exchanged, compared to its average volume of 261,544. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -31.66 and a beta of -0.21. The stock's fifty day simple moving average is $142.54 and its 200 day simple moving average is $128.12. Palvella Therapeutics has a 52 week low of $72.22 and a 52 week high of $179.95.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.08. Research analysts predict that Palvella Therapeutics will post -6.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total transaction of $537,313.54. Following the sale, the chief operating officer directly owned 2,165 shares in the company, valued at $269,715.70. This represents a 66.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Kiritsy sold 313 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the transaction, the director directly owned 250 shares in the company, valued at approximately $39,250. This represents a 55.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 61,056 shares of company stock valued at $8,756,946 over the last quarter. 17.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PVLA. Royce & Associates LP boosted its stake in Palvella Therapeutics by 24.7% in the third quarter. Royce & Associates LP now owns 50,509 shares of the company's stock valued at $6,967,000 after buying an additional 10,000 shares in the last quarter. ACT Capital Partners L.P. bought a new position in Palvella Therapeutics in the third quarter valued at about $3,103,000. William Blair Investment Management LLC bought a new position in Palvella Therapeutics in the third quarter valued at about $26,906,000. Russell Investments Group Ltd. raised its stake in Palvella Therapeutics by 114.3% during the third quarter. Russell Investments Group Ltd. now owns 47,892 shares of the company's stock worth $6,606,000 after acquiring an additional 25,547 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new position in Palvella Therapeutics during the third quarter worth about $7,259,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania.

Its pipeline includes QTORIN-based topical drug candidates, which use the company's platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Palvella is led by founder and Chief Executive Officer Wes Kaupinen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.